AEMD

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Wall Street analysts forecast AEMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AEMD is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aethlon Medical Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Aethlon Medical Inc. EPS for the last quarter amounts to -37.41 USD, increased 132.22 % YoY.

Aethlon Medical Inc (AEMD) has 9 emplpoyees as of December 16 2025.

Today AEMD has the market capitalization of 2.32M USD.